{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+Device&page=2",
    "query": {
      "intervention": "Electroporation Device",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+Device&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T12:12:28.053Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05293249",
      "title": "dMAbs for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "dMAb AZD5396",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "dMAb AZD8076",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hylenex",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Pablo Tebas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 61,
      "start_date": "2022-05-19",
      "completion_date": "2025-11-21",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05293249"
    },
    {
      "nct_id": "NCT01260727",
      "title": "Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PENNVAX-G DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-CMDR Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo PENNVAX-G Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo MVA-CMDR Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 92,
      "start_date": "2010-02",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01260727"
    },
    {
      "nct_id": "NCT04336410",
      "title": "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-04-03",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04336410"
    },
    {
      "nct_id": "NCT05743595",
      "title": "Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unmethylated Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Personalized Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDS-IM v 2.0 electroporation device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2023-10-27",
      "completion_date": "2029-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743595"
    },
    {
      "nct_id": "NCT01502345",
      "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemorrhagic Fever With Renal Syndrome"
      ],
      "interventions": [
        {
          "name": "Vaccine/device combination for prevention of HFRS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 31,
      "start_date": "2012-01",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502345"
    },
    {
      "nct_id": "NCT01082692",
      "title": "Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1 Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PENNVAX-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2011-01",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-11-09",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082692"
    },
    {
      "nct_id": "NCT06765356",
      "title": "Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Persistent Atrial Fibrillation",
        "Paroxysmal Atrial Fibrillation",
        "Long-standing Persistent Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Farapulse Catheter System",
          "type": "DEVICE"
        },
        {
          "name": "Low-dose Colchicine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Vivek Reddy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2025-04-15",
      "completion_date": "2027-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 9,
      "location_summary": "Jonesboro, Arkansas • Ventura, California • Naples, Florida + 5 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06765356"
    },
    {
      "nct_id": "NCT04397003",
      "title": "Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "TDS-IM v2.0 Device",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-03-30",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04397003"
    },
    {
      "nct_id": "NCT02204098",
      "title": "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Carcinoma",
        "Malignant Neoplasm of Breast"
      ],
      "interventions": [
        {
          "name": "Mammaglobin-A DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Optional biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2015-01-07",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204098"
    },
    {
      "nct_id": "NCT03132675",
      "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III/IV Melanoma"
      ],
      "interventions": [
        {
          "name": "tavokinogene telseplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ImmunoPulse",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2017-10-03",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-09-27T12:12:28.053Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132675"
    }
  ]
}